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1065-173 Effects of Pioglitazone on Endothelial Function and 
Aortic Stiffness in Patients With Type 2 Diabetes 
Mellitus
Hideki Watanabe, Kunio Nakagawa, Masaaki Kakihana, Kinu Medical Association 
Hospital, Mitsukaido, Japan, Ibaraki Prefectural University of Health Sciences, Ami, 
Japan
Background: Endothelial dysfunction has been reported in patients with diabetic melli-
tus (DM). Insulin resistance plays an important role in the pathogenesis of endothelial
dysfunction. We assessed the effects of pioglitazone on endothelial function and aortic
stiffness and exercise tolerance in diabetic patients. Methods: Twenty patients with
untreated type 2 DM were randomized to receive pioglitazone (Piog group: n=10, 15-30
mg/day) or not to receive pioglitazone (Cont group: n=10) after the standard therapy.
Flow-mediated dilatation (FMD) and Nitroglycerin-induced dilatation (NID) of brachial
artery were measured by using ultrasound system. We also measured aortic pulse wave
velocity (PWV) to evaluate aortic stiffness by using oscilometric technique (form PWV/
ABI ®, COLIN). These measurements were performed at baseline and then at 3 and 6
months after the treatment. Results: At baseline, there was no difference in glucose
level, HbA1c, HOMA-IR, FMD, NID, and PWV between two groups. There is no difference
in glucose level and HbA1c at 3 and 6 months between two groups, but HOMA-IR and
systolic blood pressure were significantly decreased after 6 months in the Piog group.
FMD was significantly increased after 3 and 6 months in the Piog group. PWV was signif-
icantly decreased after 6 months in the Piog group. NID did not change during the study
in two groups. Conclusion: Pioglitazone improves not only insulin resistance, but also
endothelial function and aortic stiffness in patients with type 2 DM.
1065-174 Early Morning Impairment of Endothelial Function in 
Healthy Humans
Rodrigo B. Barretto, Maria E. Otto, Anna Svatikova, Simone Santos, Michal Hoffmann, 
Bijoy Khandheria, Virend K. Somers, Mayo Clinic, Rochester, MN
Background: Cardiovascular events, such as myocardial infarction, sudden death, and
stroke have a peak incidence in the early hours after waking. The mechanisms involved
in this circadian variation are not clear. Endothelial dysfunction is associated with
increased risk for cardiovascular events. We tested the hypothesis that endothelial func-
tion is impaired in the early morning, around the time of waking, in comparison to mea-
surements obtained both before sleep, and later in the day, in healthy humans.
Methods: We studied 28 healthy subjects (mean age: 41 years, mean body mass index:
27.8 kg/m2, 19 male, 9 female). All participants had no history of cardiovascular or other
diseases, smoking or diabetes, and were not taking any medication. All volunteers under-
went polysomnography to exclude obstructive sleep apnea or other sleep disorders.
Endothelial function was measured by brachial artery percent changes of diameter after
ischemia, flow-mediated endothelium-dependent vasodilation (FMD), and after nitroglyc-
erin, endothelium-independent vasodilation (non-flow mediated vasodilation-NFMD), on
three different occasions; first, before the subjects went to sleep (9:00PM); second, in the
morning immediately after waking (6:00AM); and third, during the late morning, five hours
after waking (11:00PM).
Results: Values are expressed as mean ± SE. All subjects had normal sleep with good
sleep efficiency of 84 ± 2.3 %. Compared to prior to sleep, FMD decreased markedly in
the early morning after waking, and recovered by late morning (9:00PM: 6.8 ± 0.8%;
6:00AM: 4.4 ± 0.7%; 11:00AM: 7.04 ± 0.7%; p=0.035). NFMD was similar for the three
periods of observation (9:00PM: 16.9 ± 1.5%, 6:00AM: 16.7 ± 1.3% and 11:00AM: 18.1 ±
1.7%, p=NS).
Conclusions: Endothelial-mediated vasodilation is blunted in the early morning in
healthy subjects. Impairment of endothelial function in the early morning may have impli-
cations for understanding the morning peak in cardiac and vascular events.
1065-175 Effects of Allopurinol on Endothelial Function and 
Nitrate Tolerance in Type 2 Diabetics With Stable Angina
Hideki Watanabe, Kunio Nakagawa, Masaaki Kakihana, Kinu Medical Association 
Hospital, Mitsukaido, Japan, Ibaraki Prefectural University of Health Sciences, Ami, 
Japan
Background: Diabetic patients have endothelial dysfunction due to increased oxidative
stress. Continuous treatment with nitroglycerin (NTG) increases oxidative stress, and
induces not only nitrate tolerance, but also NTG-induced endothelial dysfunction. Xan-
thine oxidase is known as one of the sources of superoxide. We assessed the effects of
allopurinol, a xanthine oxidase inhibitor, on endothelial function, nitrate tolerance, and
NTG-induced endothelial dysfunction. Methods: Twenty-four type 2 diabetics with stable
angina were randomized to receive allopurinol (Allo group: n=12, 300 mg/day) or not to
receive allopurinol (Cont group, n=12). Flow-mediated dilatation (FMD) and NTG-
induced dilatation (NID) of brachial artery were measured by using high resolution ultra-
sound system. These measurements were performed in 12-hour overnight fasting condi-
tion at baseline, and then at 1 month after the therapy with allopurinol (1 Mo) and 1
month after the therapy with allopurinol and NTG patch 25 mg/day (2 Mo). Results: At
baseline, there was no difference in glucose level, HbA1c, FMD and NID between two
groups. FMD was significantly increased at 1 Mo in the allo group, but was significantly
decreased at 2 Mo in the both group. NID did not change at 1 Mo in the both groups, but
was significantly decreased at 2 Mo in the both groups. Conclusion: Allopurinol
improves endothelial function, but does not prevent nitrate tolerance and NTG-induced
endothelial dysfunction in type 2 diabetics with stable angina.
1065-176 Role of Endothelin-1 and Coronary Flow Reserve in 
Hypertensive Patients Without Coronary Artery Disease
Hideki Fujii, Shin Takiuchi, Shinichirou Niizuma, Kei Kamide, Takeshi Horio, Satoshi 
Nakatani, Yuhei Kawano, National Cardiovascular Center, Suita, Japan
Background:
It is suggested that hypertensive patients with angina pectoris and normal coronary arte-
riograms have reduced coronary flow reserve (CFR) due to microvascular dysfunction.
Endothelin-1 (ET-1) is a potent vasoconstrictor, and an important modulator of microvas-
cular function. However, there were few comparative investigations of CFR and ET-1 as a
cause of the disease. The aim of this study was to evaluate plasma ET-1 levels and its
association with the CFR in symptomatic hypertensive patients without coronary artery
disease.
Methods:
A total of 62 patients with essential hypertension who are free of coronary artery disease
(28 men and 34 women, mean 61 ± 10 years old) were included in the present study.
Coronary artery disease was ruled out by coronary angiogram or exercise stress scintig-
raphy. Plasma concentrations of ET-1 were measured in patients with having a history of
typical angina-like chest pain (n=33) and without symptoms (n=29). CFR was measured
using adenosine-triphosphate stress transthoracic Doppler echocardiography. Conven-
tional echocardiography and carotid ultrasonography were performed to assess left ven-
tricular mass index (LVMI) and carotid intima-media thickness (IMT).
Results:
Mean value of plasma ET-1 level was 3.5 ± 1.3 pg/ml, and CFR was 2.49 ± 0.60. Each
parameter significantly correlated with the other (r=0.409, p < 0.0001). Mean concentra-
tion of ET-1 was higher in symptomatic group than in asymptomatic group (4.0 ± 1.3 pg/
ml vs. 2.9 ± 1.1 pg/ml, respectively), while CFR was significantly lower in symptomatic
group than in asymptomatic group (2.27 ± 0.50 vs. 2.75 ± 0.62, respectively). Prevalence
of LVH (LVM index > 50 g/m2.7) was similar between the two groups, but carotid IMT was
significantly greater in symptomatic group.
Conclusion:
Plasma ET-1 is raised in hypertensive patients with angina-like chest pain but without
coronary artery disease, and is associated with reduced CFR. The current study sug-
gests that the impaired CFR in hypertensive patients is associated with endothelial dys-
function due to subclinical atherosclerosis and ET-1 may play a role in the disease
process.
Baseline 3 months 6 months
Systolic BP (mmHg) Pioglitazone 147+/-9 147+/-8 136+/-5*#
Control 146+/-8 147+/-7 148+/-6
HOMA-IR Pioglitazone 2.9+/-0.4 2.2+/-0.6* 1.8+/-0.3*#
Control 3.0+/-0.4 2.5+/-0.6 2.4+/-0.6
FMD (%) Pioglitazone 4.9+/-1.7 7.6+/-1.4*# 9.4+/-1.3*#
Control 5.2+/-1.3 5.7+/-1.1 5.5+/-1.2
NID (%) Pioglitazone 14.5+/-1.1 14.5+/-0.9 14.7+/-1.3
Control 14.1+/-1.7 13.9+/-1.2 14.0+/-1.1
PWV (cm/sec) Pioglitazone 1535+/-69 1536+/-83 1369+/-53*#
Control 1522+/-82 1523+/-83 1519+/-75
Data are mean+/-SD. *p<0.01 vs Baseline, #p<0.01 vs Control
Flow-mediated dilatation (FMD) and NTG-induced dilatation (NID)
Baseline 1 month 2 months
FMD (%) Allopurinol 5.2 +/- 1.1 8.5 +/- 1.8*§ 4.1 +/- 1.2*#
Control 5.4 +/- 1.2 5.6 +/- 1.4 4.0 +/- 1.3*#
NID (%) Allopurinol 14.6 +/- 1.4 14.5 +/- 1.5 9.3 +/- 1.2*#
Control 14.8 +/- 1.5 14.7 +/- 1.6 8.7 +/- 1.3*#
Data are mean+/-SD. *p<0.01 vs Baseline, #p<0.01 vs 1 month, §p<0.01 vs Control 
group
